<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621526</url>
  </required_header>
  <id_info>
    <org_study_id>6434</org_study_id>
    <nct_id>NCT04621526</nct_id>
  </id_info>
  <brief_title>Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol For Chronic Subdural Hematoma</brief_title>
  <official_title>Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol Combination During Burr-Hole Surgery For Chronic Subdural Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inadequate sedation and analgesia indicated by intraoperative movements are markers of&#xD;
      inadequate MAC during burr-hole surgery for chronic subdural hematoma evacuation especially&#xD;
      when general anesthesia poses high risk for the patients.&#xD;
&#xD;
      Dexmedetomidine, ketamine, propofol intravenous infusion and other agents was used to provide&#xD;
      monitored anesthesia care with variable success if used as solitary agents as each drug has&#xD;
      its limited use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size: Assuming that the mean ± SD of the onset time of sedation was 50.2±4.9 seconds&#xD;
      in propofol group versus 53.8±6.1 seconds in dexmedetomidine-propofol group (9). So the total&#xD;
      sample size is 76 cases (38 in each group) using Open Epi Info with confidence interval 95%&#xD;
      and power of test is 80%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The onset time of sedation</measure>
    <time_frame>with in 30 minutes before start of surgery</time_frame>
    <description>The onset of sedation will be recorded. It is defined as the time from injection of sedative medications till reaching a target sedation level score 3 by modified Observer's Assessment of Alertness and sedation score (OAA/S).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The extent of airway obstruction</measure>
    <time_frame>intraopertive</time_frame>
    <description>The extent of airway obstruction by (1= patent airway, 2= airway obstruction alleviated by jaw thrust, 3= airway obstruction alleviated by positive mask ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rescue analgesic (fentanyl)</measure>
    <time_frame>intraoperative</time_frame>
    <description>Total number of calling intraoperative rescue analgesic (fentanyl) in both groups will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participant with complications</measure>
    <time_frame>intraoperative</time_frame>
    <description>Intraoperative complications such as hypotension (mean arterial blood pressure decreases by &gt; 20% of basal reading), bradycardia (HR decreases by &gt; 20% of basal reading) and bradypnea (RR less than 10 b/m) or hypoxemia (SpO2 less than 95%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>with in one hour postoperative</time_frame>
    <description>Recovery time: time from discontinuation of infusion drugs till spontaneous eye opening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain intensity</measure>
    <time_frame>at 30 minutes then at 1, 2, 4, 6 and 12 hours postoperative</time_frame>
    <description>Postoperative Pain intensity will be evaluated using Visual Analogue Scale (VAS) . A commonly used scale is a 10-cm line labeled with &quot;worst pain imaginable&quot; on the left border and &quot;no pain&quot; on the right border. The patient is instructed to make a mark along the line to represent the intensity of pain currently being experienced. It will be assessed at 30 minutes, 2h, 4h and 6h till 12h postoperative. Paracetamol 1gm IV will be given every 6 hours as a protocol for pain management, and IV pethidine 50 mg (rescue analgesic) will be given if VAS≥4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Neurological status of participants</measure>
    <time_frame>at baseline then within one hour postoperative</time_frame>
    <description>The Neurological status of participants will be assessed before discharge in the PACU using Markwalder's Neurological Grading scale (MNGs) and recorded:&#xD;
Grade 0: no neurologic deficit Grade I: mild symptoms such as headache; absent or mild neurologic deficits such as reflex asymmetry Grade II: drowsiness or disorientation with variable neurologic deficits such as hemiparesis Grade III: stupor, but appropriate responses to noxious stimuli; severe focal signs such as hemiplegia Grade IV: coma with absence of motor response to painful stimuli; decerebrate or decorticate posturing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and surgeon satisfaction</measure>
    <time_frame>with in 24 hours after surgery</time_frame>
    <description>Patient and surgeon satisfaction using 7- point Likert-like verbal rating scale by asking about how they evaluate their experience with anesthetic management during surgery?&quot; score will be 6 and 7 if they are satisfied.5=very satisfied, 4=satisfied, 3= neutral, 2= unsatisfied and 1= very unsatisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine- ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive combination of ketamine 1.5mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine- propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine- ketamine</intervention_name>
    <description>patients will receive combination of ketamine 1.5mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.</description>
    <arm_group_label>dexmedetomidine- ketamine</arm_group_label>
    <other_name>precedex- katalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine- propofol</intervention_name>
    <description>patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.</description>
    <arm_group_label>dexmedetomidine- propofol</arm_group_label>
    <other_name>precedex- diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient acceptance.&#xD;
&#xD;
          -  Both sex.&#xD;
&#xD;
          -  Age (50-80) years old.&#xD;
&#xD;
          -  Patient with Body Mass Index (BMI) (25-30kg/m²).&#xD;
&#xD;
          -  American Society of Anesthesiologist (ASA) II / III&#xD;
&#xD;
          -  patient scheduled to burr-hole surgery for chronic subdural hematoma evacuation under&#xD;
             MAC.&#xD;
&#xD;
          -  Markwalder's Neurological Grading scale (MNGs) score &lt;2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with difficult airway (mallapati III,IV).&#xD;
&#xD;
          -  Altered mental status (psychiatric and anexity disorder).&#xD;
&#xD;
          -  Post-traumatic stress disorders.&#xD;
&#xD;
          -  History of allergy to study drugs.&#xD;
&#xD;
          -  Patient on sedative or hypnotic medication.&#xD;
&#xD;
          -  Patients with on painkiller.&#xD;
&#xD;
          -  Patients with any degree of heart block.&#xD;
&#xD;
          -  Sever liver, respiratory or renal impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alshaimaa Kamel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zagazig University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alshaimaa Kamel, M.D</last_name>
    <phone>01005593169</phone>
    <phone_ext>002</phone_ext>
    <email>AlshaimaaKamel80@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salwa ElSherbeny, M.D</last_name>
    <phone>01128595629</phone>
    <phone_ext>002</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig University Hospitsals</name>
      <address>
        <city>Zagazig</city>
        <zip>055</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alshaimaa Kamel, MD</last_name>
      <phone>01005593169</phone>
      <phone_ext>002</phone_ext>
      <email>AlshaimaaKamel80@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Salwa ElSherbeny, MD</last_name>
      <phone>01128595629</phone>
      <phone_ext>002</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Alshaimaa Kamel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Alshaimaa Abdel Fattah Kamel</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

